Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug609 | COVID-19 convalescent hyperimmune plasma Wiki | 0.45 |
drug1910 | Magnetic Resonance Spectroscopy (MRS). Wiki | 0.45 |
drug683 | Cannabis, Medical Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
drug607 | COVID-19 antibody point of care test kit Wiki | 0.45 |
drug2198 | Non-convalescent fresh frozen plasma (Standard plasma) Wiki | 0.45 |
drug456 | Blink and Masseter Inhibitory Reflex Wiki | 0.45 |
drug608 | COVID-19 barrier box Wiki | 0.45 |
drug606 | COVID-19 antibodies testing Wiki | 0.45 |
drug313 | Auditory Evoked Potentials (AEP) Wiki | 0.45 |
drug376 | BNT162b1 Wiki | 0.26 |
drug377 | BNT162b2 Wiki | 0.22 |
drug2448 | Placebo Wiki | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
D000070642 | Brain Injuries, Traumatic NIH | 0.63 |
D000070627 | Chronic Traumatic Encephalopathy NIH | 0.45 |
D013226 | Status Epilepticus NIH | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D002543 | Cerebral Hemorrhage NIH | 0.45 |
D013345 | Subarachnoid Hemorrhage NIH | 0.45 |
D005879 | Tourette Syndrome NIH | 0.45 |
D003424 | Crohn Disease NIH | 0.45 |
D005356 | Fibromyalgia NIH | 0.32 |
D000690 | Amyotrophic Lateral Sclerosis NIH | 0.32 |
D012640 | Seizures NIH | 0.32 |
D016472 | Motor Neuron Disease NIH | 0.32 |
D006526 | Hepatitis C NIH | 0.32 |
D001714 | Bipolar Disorder NIH | 0.32 |
D013119 | Spinal Cord Injuries NIH | 0.26 |
D006470 | Hemorrhage NIH | 0.26 |
D014947 | Wounds and Injuries NIH | 0.25 |
D000755 | Anemia, Sickle Cell NIH | 0.22 |
D001927 | Brain Diseases NIH | 0.20 |
D010300 | Parkinsonian NIH | 0.18 |
D009461 | Neurologic Manifestations NIH | 0.18 |
D009103 | Multiple Sclerosis NIH | 0.17 |
D015212 | Inflammatory Bowel Diseases NIH | 0.17 |
D012598 | Scoliosi NIH | 0.16 |
D059350 | Chronic Pain NIH | 0.15 |
D020521 | Stroke NIH | 0.12 |
D004194 | Disease NIH | 0.09 |
D040921 | Stress Disorders, Traumatic NIH | 0.09 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.08 |
D013577 | Syndrome NIH | 0.04 |
D003141 | Communicable Diseases NIH | 0.03 |
D007239 | Infection NIH | 0.02 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
D018352 | Coronavirus Infections NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002133 | Status epilepticus HPO | 0.45 |
HP:0002138 | Subarachnoid hemorrhage HPO | 0.45 |
HP:0001342 | Cerebral hemorrhage HPO | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100280 | Crohn's disease HPO | 0.45 |
HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.32 |
HP:0100754 | Mania HPO | 0.32 |
HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.32 |
HP:0001250 | Seizure HPO | 0.26 |
HP:0001298 | Encephalopathy HPO | 0.20 |
HP:0002037 | Inflammation of the large intestine HPO | 0.17 |
HP:0012532 | Chronic pain HPO | 0.15 |
HP:0001297 | Stroke HPO | 0.12 |
Navigate: Correlations HPO
There are 5 clinical trials
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsAlthough direct evidence is currently lacking, the high identity between SARS-CoV-1 and SARS-CoV-2 suggests, that the latter viral strain could also infect the Central Nervous System (CNS). Indeed, some cases of SARS-COV2 encephalitis begin to be described and CNS damages are increasingly highlighted in the literature, but still not objectified by imaging and do not allow to explain the entire clinical patterns. We hypothesise that these CNS damages are not always objectified by Magnetic Resonance Imaging (MRI) but could be indirectly observed by a physiological dysfunction of neural conduction in the brainstem. We will explore brainstem disruption through an electrophysiological approach.
Description: Latencies of electrophysiological responses with Auditory Evoked Potentials
Measure: Latency of electrophysiological response Time: Inclusion (T0)Description: Delay of Muscle contraction (Blink reflex)
Measure: Delay of Muscle contraction Time: Inclusion (T0)Description: Delay of silent period while the patient is asked to tighten the jaws (Masseter Inhibitory Reflex)
Measure: Delay of silent period Time: Inclusion (T0)Description: Duration of silent period while the patient is asked to tighten the jaws (Masseter Inhibitory Reflex)
Measure: Duration of silent period Time: Inclusion (T0)Description: Inhibition rate while the patient is asked to tighten the jaws (Masseter Inhibitory Reflex)
Measure: Inhibition rate Time: Inclusion (T0)Document and evaluate the impact of societal restrictions due to the pandemic on SCI- and ABI-related disability and functional impairments, and the resultant effects on psychological wellbeing, physical wellbeing and quality of life for those with SCI/ABI.
Description: Fear of COVID-19 Questionnaire
Measure: Change in Fear of COVID-19 Time: baseline, 3 months, 6 monthsDescription: NeuroQol SF v1.0 - Ability to Part. in SRA
Measure: Change in ability to participate in social roles and activities Time: baseline, 3 months, 6 monthsDescription: NeuroQol SF v1.0 - Depression
Measure: Change in depressive symptoms Time: baseline, 3 months, 6 monthsDescription: NeuroQol SF v1.0 - Pos. Affect & Well-Being
Measure: Change in positive affect and well-being Time: baseline, 3 months, 6 monthsDescription: NeuroQol SF v1.0 - Anxiety
Measure: Change in anxiety Time: baseline, 3 months, 6 monthsDescription: NeuroQol SF v1.0 - Fatigue
Measure: Change in fatigue Time: baseline, 3 months, 6 monthsDescription: NeuroQol SF v1.0 - Emotional & Beh. Dyscontrol
Measure: Change in emotional and behavioural dyscontrol Time: baseline, 3 months, 6 monthsDescription: NeuroQol SF v1.0 - Satisfaction w SRA
Measure: Change in satisfaction with social roles and activities Time: baseline, 3 months, 6 monthsDescription: NeuroQol SF v1.0 - Sleep Disturbance
Measure: Change in sleep disturbance Time: baseline, 3 months, 6 monthsDescription: NeuroQol SF v1.0 - Stigma
Measure: Change in stigma Time: baseline, 3 months, 6 monthsDescription: NeuroQol SF v1.0 - Cognitive Function
Measure: Change in cognitive function Time: baseline, 3 months, 6 monthsDescription: 23 questions about strategies to social distance
Measure: Change in social distancing strategies used Time: baseline, 3 months, 6 monthsDescription: 22 questions about social distancing
Measure: Change in thoughts and feelings about social distancing Time: baseline, 3 months, 6 monthsA prospective cohort minimal risk study to determine the impact of the COVID-19 crisis on outcomes of neurologically injured ICU patients.
Description: Care treatment such as ventilator use, intubation, and/or tracheostomy
Measure: Limitations of patient care- Frequency of care not being provided Time: During In-hospital course, up to 1 monthViral pandemics, such as HIV and SARS-Cov-V1, have shown that they can lead to acute and / or delayed neurological complications. At the actual context of the pandemic Coronavirus disease 2019 (COVID-19), neurological manifestations seem to be confirmed since in 85% of COVID-19 patients, present neurological symptoms, including anosmia, ageusia, periorbital pain, dizziness, fatigue, even moderate headache, moderate memory and/or behavioral disorders. However, these neurological manifestations are not well studied and their radiological features are not well described. It is therefore important to assess these potential neurological complications in COVID-19 patients. To the investigator knowledge, there is no previous study in the literature describing spectral brain changes in COVID + patients. Thus, the goal of this work is to describe the radiological semiology using MRI and particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the evaluation of acute and / or delayed brain damage in COVID + patients presenting a neurological manifestations that are initially related to the cranial nerves damage.
Description: The radiological semiology as described by MRI and particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the COVID-19 patients presenting neurological manifestations related initially to the cranial nerves damage.
Measure: Variation from baseline of MRI radiological semiology in COVID-19 patients Time: 9 months after patient inclusionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports